➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Mallinckrodt
Colorcon
Harvard Business School
Medtronic

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXEMESTANE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Exemestane

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002777 ↗ Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1996-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen. PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
NCT00003418 ↗ Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗ Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status UNICANCER Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 ↗ Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status International Collaborative Cancer Group Phase 3 1998-02-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00010010 ↗ Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 2000-06-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 ↗ Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed New York University School of Medicine Phase 2 2000-06-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00016432 ↗ Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen Completed National Cancer Institute (NCI) Phase 3 2001-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen by the tumor cells. It is not yet known whether exemestane is effective in preventing the recurrence of breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of exemestane in preventing cancer recurrence in postmenopausal women who have resected stage I, stage II, or stage IIIA breast cancer and have completed 5 years of tamoxifen.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exemestane

Condition Name

Condition Name for Exemestane
Intervention Trials
Breast Cancer 95
Breast Neoplasms 25
Metastatic Breast Cancer 21
HER2/Neu Negative 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exemestane
Intervention Trials
Breast Neoplasms 187
Neoplasms 10
Breast Neoplasms, Male 5
Carcinoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exemestane

Trials by Country

Trials by Country for Exemestane
Location Trials
United States 808
Italy 106
Canada 93
United Kingdom 60
Japan 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exemestane
Location Trials
California 35
Texas 34
Florida 34
New York 32
Massachusetts 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exemestane

Clinical Trial Phase

Clinical Trial Phase for Exemestane
Clinical Trial Phase Trials
Phase 4 9
Phase 3 51
Phase 2/Phase 3 1
[disabled in preview] 147
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exemestane
Clinical Trial Phase Trials
Recruiting 56
Completed 55
Active, not recruiting 33
[disabled in preview] 63
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exemestane

Sponsor Name

Sponsor Name for Exemestane
Sponsor Trials
Pfizer 32
National Cancer Institute (NCI) 31
Novartis Pharmaceuticals 17
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exemestane
Sponsor Trials
Other 190
Industry 121
NIH 34
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
McKinsey
Harvard Business School
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.